General Hospital Sibenik
- Address
- Stjepana Radica 83, 22000 Sibenik, Croatia
General Hospital Sibenik - Myeloproliferative Neoplasms Research Center
General Hospital Sibenik is a specialized clinical research facility focused on advancing treatment options for patients with myeloproliferative neoplasms (MPNs). The center demonstrates significant expertise in conducting Phase 3 clinical trials evaluating novel therapeutic approaches for complex hematologic malignancies, with particular emphasis on improving patient outcomes through innovative drug combinations and targeted therapies.
- Primary Myelofibrosis treatment strategies, including combination therapies with ruxolitinib and investigational agents targeting spleen volume reduction and symptom management
- Polycythemia Vera research in JAK2V617F-positive high-risk patients, evaluating histone deacetylase inhibitors and comparative efficacy studies
- Long-term safety and tolerability assessment of emerging therapies for chronic myeloproliferative disorders
The hospital's research program emphasizes both efficacy endpoints such as spleen volume reduction and total symptom score improvement, as well as comprehensive evaluation of treatment safety profiles. Their participation in multinational trials positions them as a key contributor to the development of next-generation therapies for patients with JAK2-mutated myeloproliferative neoplasms, ultimately working to expand treatment options for this challenging patient population.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 2 by active trials.
- 1Italfarmaco S.p.A.1active
lock +1 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 60 other sites in Croatia
Therapeutic Area Benchmark — Croatia
Select a therapeutic area to compare against other sites in Croatia.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Croatia
Market Share
Country: Croatia
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in General Hospital Sibenik
lock Showing 1 of 2 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Phase 3 Randomized Study of Navtemadlin and Ruxolitinib Versus Placebo and Ruxolitinib in Myelofibrosis Patients with Suboptimal Ruxolitinib Response | Kartos Therapeutics Inc. | Phase III | Recruiting | Oct 2024 | — |
IMP list
lock Showing 1 of 10 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Carbasalate Calcium | 1 | Unknown | 2024-04-25 | 2024-04-25 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.